Physician profile
Jonathan Hugo
NPI 1306041009
$5,844.22
in general payments reported to CMS, 2019-2025
37 companies · $2,299 in 2025
The $2,299 reported for 2025 was more than what 79% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $75.11 · 2021: $105 · 2023: $1,392 · 2024: $1,779 · 2025: $2,299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,440 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,439.77 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $692.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $624.18 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.46 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Medtronic, INC. | $436.76 | 2023-2025 | Minimed 780g, Inceptiv |
| Corcept Therapeutics | $435.82 | 2023-2025 | Korlym |
| Sanofi-Aventis U.S. LLC | $398.64 | 2023-2025 | |
| Dexcom, INC. | $337.80 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Tandem Diabetes Care, INC. | $330.93 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Xeris Pharmaceuticals, INC. | $328.08 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Insulet Corporation | $311.96 | 2019-2025 | Omnipod |
| Medtronic Minimed, INC. | $227.40 | 2019-2020 | |
| Amgen INC. | $206.61 | 2023-2025 | Evenity, Tepezza, Prolia |
| Sequel Med Tech, LLC | $158.71 | 2025 | Twiist |
| Beta Bionics, INC. | $71.68 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Ascensia Diabetes Care US INC. | $68.67 | 2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rgh Enterprises LLC | $62.27 | 2025 | |
| Ibsa Pharma INC. | $53.89 | 2025 | Licart, Tirosint, Flector |
| Abbvie INC. | $49.22 | 2025 | |
| Madrigal Pharmaceuticals | $48.37 | 2025 | Rezdiffra |
| Abbott Laboratories | $45.69 | 2025 | Freestyle Insulinx, Freestyle Libre 3 |
| Janssen Biotech, INC. | $35.02 | 2023-2024 | Simponi Aria, Stelara, Simponi |
| Antares Pharma, INC. | $34.98 | 2024-2025 | Xyosted |
| Halozyme INC | $33.10 | 2023 | |
| Alexion Pharmaceuticals, INC. | $33.00 | 2025 | Strensiq |
| Novartis Pharmaceuticals Corporation | $32.72 | 2024-2025 | |
| Amphastar Pharmaceuticals, INC. | $28.87 | 2024-2025 | |
| Ucb, INC. | $22.49 | 2025 | Bimzelx |
| Cequr Corporation | $18.64 | 2024 | Cequr Simplicity |
| Neurocrine Biosciences, INC. | $18.18 | 2024 | |
| Ascendis Pharma Endocrinology INC | $17.77 | 2025 | Yorvipath |
| Endo USA, INC. | $16.68 | 2025 | Aveed |
| Tactile Systems Technology INC | $16.52 | 2023 | Flexitouch Plus, Entre Plus |
| Seapearl East, INC | $15.92 | 2025 | |
| Glaxosmithkline, LLC. | $14.63 | 2025 | Shingrix |
| Sun Pharmaceutical Industries INC. | $14.57 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $13.97 | 2024 | Farxiga |
| Boston Scientific Corporation | $13.58 | 2025 | Wavewriter Alpha Prime 16 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Hugo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.